Supreme Court Hears Skinny Label Arguments in Hikma v. Amarin, Signaling Impact on Hatch-Waxman Carve-Out Strategy (JSON)

lexblog.com/lib/PW4XAH41view recordjson

{
    "@context": "https://schema.org",
    "@type": "Article",
    "headline": "Supreme Court Hears Skinny Label Arguments in Hikma v. Amarin, Signaling Impact on Hatch-Waxman Carve-Out Strategy",
    "url": "https://www.lexblog.com/2026/05/20/supreme-court-hears-skinny-label-arguments-in-hikma-v-amarin-signaling-impact-on-hatch-waxman-carve-out-strategy/",
    "identifier": {
        "@type": "PropertyValue",
        "name": "LexBlog Library record",
        "value": "LEX-WK-PW4XAH41",
        "url": "https://www.lexblog.com/lib/PW4XAH41/"
    },
    "datePublished": "2026-05-20T14:30:59-04:00",
    "dateModified": "2026-05-20T14:56:18-04:00",
    "author": {
        "@type": "Person",
        "name": "Anh-Thu Lam, Aydin H. Harston"
    },
    "sourceOrganization": {
        "@type": "Organization",
        "name": "Rothwell Figg"
    },
    "organizationScope": "at-publication",
    "isPartOf": "Biosimilars Law Bulletin",
    "about": "Health Care and Life Sciences · Intellectual Property",
    "sourceUrl": "https://www.biosimilarsip.com/?p=5895",
    "sourceStability": "may-move"
}